RxDoctor Payments Data

Sultan Yusufzai, MD

Internal Medicine · Rancho Cordova, CANPI 1831479815

Payments from drug & device makers

$13,229in general payments, 2019–2025

Across 678 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$915
  • Bayer$579
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$13,217100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)109$2,008
GSK85$1,802
AstraZeneca(2 entities)49$1,092
Novo Nordisk72$1,029
Lilly USA, LLC49$915
Bayer31$579
Jazz Pharmaceuticals Inc.20$544
Novartis25$452
Boehringer Ingelheim26$436
Amgen19$385
Exact Sciences14$353
Aimmune Therapeutics, Inc.16$352
Pfizer13$287
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$267
Amarin Pharma, Inc.10$196
Sunovion Pharmaceuticals Inc.16$186
Nestle Healthcare Nutrition Inc.6$160
Otsuka America Pharmaceutical, Inc.7$156
Sanofi-aventis U.S. LLC7$145
Astellas Pharma US Inc6$140
Merck8$136
Avanir Pharmaceuticals, Inc.6$116
E.r. Squibb & Sons, L.L.C.6$111
Esperion Therapeutics, Inc.4$95
Neurocrine Biosciences, Inc.3$92
Urovant Sciences Inc3$92
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$78
Siemens Medical Solutions USA, Inc.1$74
Johnson & Johnson4$71
Axsome Therapeutics, Inc.2$69
Organogenesis Inc.2$65
Boston Scientific2$51
Sun Pharmaceutical Industries Inc.2$49
Acadia Pharmaceuticals Inc3$49
Dexcom, Inc.2$44
Scilex Pharmaceuticals Inc.2$43
Mayne Pharma Commercial LLC2$40
Phadia US Inc.2$35
Biohaven Pharmaceuticals, Inc.2$34
Abbott2$33
Insulet Corporation1$32
Sumitomo Pharma America, Inc.2$32
Kowa Pharmaceuticals America, Inc.2$30
Eisai Inc.2$27
Kyowa Kirin, Inc.1$26
Gilead1$24
VBI Vaccine (delaware) Inc.1$24
Alnylam Pharmaceuticals Inc.1$23
Smith+Nephew1$22
Qiagen, LLC1$20
Otsuka Pharmaceutical Development & Commercialization, Inc.1$18
Ironwood Pharmaceuticals, Inc1$18
Lexicon Pharmaceuticals, Inc.1$17
Supernus Pharmaceuticals, Inc.1$15
Alfasigma USA, Inc.1$14
Biodelivery Sciences International, Inc.1$13
Teva Pharmaceuticals USA, Inc.1$13

How this compares

$13,229 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$116,560
Medicare patients
240
Services billed
1,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$99,657
TrulicityDulaglutide58$78,413
OzempicSemaglutide51$74,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$73,191
JardianceEmpagliflozin37$51,572
FarxigaDapagliflozin Propanediol33$36,498
MounjaroTirzepatide18$33,090
RybelsusSemaglutide14$30,270
ZenpepLipase/Protease/Amylase15$19,696
JanuviaSitagliptin Phosphate13$17,734
LinzessLinaclotide19$16,894
XareltoRivaroxaban14$15,599
VascepaIcosapent Ethyl26$14,049
GemtesaVibegron33$13,665
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$915$111,50376 claims
Novo NordiskOzempic, Rybelsus$1,029$104,61265 claims
PfizerEliquis$287$99,657168 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,802$86,269106 claims
Boehringer IngelheimJardiance$436$51,57237 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,092$46,59047 claims
AbbVieLinzess, Creon, Synthroid$2,008$23,93550 claims
Aimmune Therapeutics, Inc.Zenpep$352$19,69615 claims
MerckJanuvia$136$17,73413 claims
Johnson & JohnsonXarelto$71$15,59914 claims
Sumitomo Pharma America, Inc.Gemtesa$32$13,66533 claims
Astellas Pharma US IncMyrbetriq$140$9,75014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Cordova

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →